Following reports of NDMA impurity, CDSCO has directed state drug controllers to monitor NDMA levels in Ranitidine, a common antacid. An expert panel recommended a larger committee to investigate storage conditions and ICMR to study the drug’s safety. Manufacturers are instructed to monitor NDMA levels and take risk-based measures, potentially reducing shelf life.
